You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
The firm expects to validate its test as a triage tool to identify SARS-CoV-2 patients at risk of sepsis and pursue US FDA Emergency Use Authorization.
An international group of researchers aim to develop an approach that may be able to diagnose multiple conditions, including pneumonia, tuberculosis, sepsis, with one blood sample.
The firm said it will use the funds to advance development of its HostDx immune response gene expression tests for acute infections and sepsis.
The seven-year grant renews funding for the Antibacterial Resistance Leadership Group, led by Duke University and UCSF, with $15 million in 2020.
A bi-weekly listing of recent local coverage determinations from Medicare Administrative Contractors.
The firm said that in a first phase of the contract it will focus on further development of its fever test that analyzes immune system gene expression patterns.
The skin cancer test developer reported total revenues of $14.8 million compared to $3.7 in Q3 2018, beating the Wall Street expectation of $9.5 million.
NanoString logged $30.6 million in revenues in the third quarter, beating the Wall Street estimate of $28.1 million.
The new analysis has confirmed earlier evidence that patients with high Oncotype DX risk scores appear to benefit significantly from added chemotherapy.
CareDx will use NanoString's new Human Organ Transplant panel to develop HistoMap, a gene expression profiling test to identify allograft rejection.